Merck Acquires Rapid Micro Biosystems for $0.75 Per Share
The deal adds automated microbial quality-control testing to Merck's pharmaceutical manufacturing solutions, with closing expected in December 2026.
Updated on Nov. 17, 2026 in Healthcare

Merck has signed a definitive agreement to acquire Rapid Micro Biosystems, a US-based provider of automated microbial quality-control testing for pharmaceutical manufacturing, for US$0.75 per share in cash. The acquisition builds on a global distribution and collaboration agreement the companies announced in February 2025.
Why it matters
Quality-control laboratories face growing pressure to deliver faster testing, reliable results and better data management as biologics and advanced therapies become more complex to produce. The deal expands Merck's integrated workflow offerings for pharmaceutical manufacturers.
Merck will pay US$0.75 per share in cash for Rapid Micro Biosystems, with no total deal value or comparison to prior valuations disclosed in the announcement. The transaction is expected to close in December 2026, subject to customary closing conditions.
The players
Merck
Merck is a global pharmaceutical and life sciences company whose Life Science business supplies environmental monitoring, in-process testing and product release testing solutions.
Rapid Micro Biosystems
Rapid Micro Biosystems is a US-based company that develops automated microbial quality-control testing systems for pharmaceutical manufacturers.
The details
Rapid Micro Biosystems' Growth Direct platform automates sample incubation, imaging and microbial colony counting, and digitises sample tracking and test results. Manufacturers use it for environmental monitoring, water testing and bioburden testing, detecting microbial growth during incubation while reducing manual data entry.
Timeline
February 2025: Merck and Rapid Micro Biosystems announced a global distribution and collaboration agreement.
December 2026: The acquisition is expected to close, subject to customary conditions.
Market Landscape
The deal extends Merck's Life Science testing portfolio, which already covers environmental monitoring, in-process testing and product release testing, into automated microbial quality control. It follows a February 2025 distribution and collaboration agreement between the two companies, moving the relationship from partnership toward ownership.
For patients, the deal is unlikely to change medicines directly in the near term, since the transaction does not close until December 2026. Its effects would appear indirectly through the quality-control systems manufacturers use to test biologics and other therapies.
The takeaway
Quality-control testing is becoming a strategic part of drug manufacturing, not just a back-office function. Watch how the integration affects product availability for pharmaceutical customers after closing.
Further reading
Explore more Healthcare coverage for context on pharmaceutical manufacturing and quality-control testing.



